Cell therapy for nervous tissue repair is limited by low transplant survival. We investigated the effects of a polyurethane-based reverse thermal gel, poly(ethylene glycol)-poly(serinol hexamethylene urethane) (ESHU) on bone marrow stromal cell (BMSC) transplant survival and repair using a rat model of spinal cord contusion. Transplantation of BMSCs in ESHU at three days post-contusion resulted in a 3.5-fold increase in BMSC survival at one week post-injury and a 66% increase in spared nervous tissue volume at four weeks post-injury. 107
INTRODUCTION
Cell therapy is promising for repair of the damaged nervous system [1] [2] [3] . Bone marrow stromal cells (BMSCs) are candidate cells for such therapies because of their repair proficiency and relative accessibility [4] [5] [6] [7] . BMSCs support repair of a myriad of other ailments including cardiomyopathy, muscle dystrophy, and wound healing [8] [9] [10] . Intraneural BMSC transplants are thought to elicit repair through paracrine effects [11] [12] [13] [14] . However, these effects are likely limited due to low transplant survival in damaged nervous tissue [15] [16] [17] [18] .
Cell transplants may be lost due to various events including inflammation 19 and oxidative stress [20] [21] [22] [23] [24] , which are initiated rapidly after injury. Thus, measures to protect cell transplants against these death-mediating mechanisms may increase transplant survival and potentially improve their reparative effects. One strategy to improve transplanted cell survival is by using the synthetic poly(ethylene glycol)-poly(serinol hexamethylene urethane) or ESHU, which is a reverse thermal gel with good biocompatibility and degradability 25, 26 . ESHU is a copolymer with two hydrophilic poly(ethylene glycol) blocks flanking a hydrophobic poly(serinol hexamethylene urethane) block 25 . The presence of polyurethane 28, 29 may provide ESHU with antioxidant capacity. ESHU dissolves in water and undergoes phase transition with increasing temperatures to form a physical gel at 37C 25 , which makes it especially practical for treatment of closed injuries 30 .
ESHU was shown to have good biocompatibility with nervous tissue in the ocular system 26, 27 . A beneficial feature of ESHU is that the repeating units of the polymer contain protected amine groups providing an easy path to functionalization using biomolecules or other signaling molecules that can offer enhanced bioactivity of the gel in vivo. One example is to functionalize ESHU through these amine groups with the pentapeptide, IKVAV, which in pilot experiments was shown to produce a neural interface similar to laminin.
We hypothesized that ESHU protects intraneural BMSC transplants from death leading to improved repair. This premise was tested in vivo using an adult rat model of spinal cord contusion 7, 15, 16 assessing BMSC transplant survival, inflammation, anatomical restoration, and functional recovery and in vitro using BMSC cultures determining the effects of ESHU on survival of BMSCs under oxidative stress.
MATERIALS AND METHODS

Ethics and surgical approval
Before and after surgery, rats were housed following guidelines of the National Institutes of Health and the United States Department of Agriculture. The rats were kept within a double-barrier facility in standard rat cages with continuous supply of fresh air, water, and food. All procedures were approved by the Institutional Animal Care and Use Committee at the University of Pittsburgh.
Transplant preparation
We harvested BMSCs from femurs of female adult Sprague Dawley rats according to a previously described protocol (Fig. 1a ) 7, 15, 31 . . Fourth passage cells positive for the BMSC markers, CD90 and CD105 and negative for blood cell markers, CD34, CD45 and HLA-DR 16, 32, 33 were used for the experiments.
ESHU
The preparation of ESHU (Fig. 1b) 
Post-surgery procedures
Antisedan (1.5 mg/kg; Pfizer) was injected subcutaneously to reverse the effects of Dexdomitor 7, 15 . An intramuscular injection of gentamicin (6mg/kg; VWR), a subcutaneous injection of Rimadyl (5 mg/kg; Pfizer), and a subcutaneous injection of Ringer's solution (10 ml on surgery day, 5 ml thereafter; Butlerschein) were administered daily for the first three days post-injury 7, 15 . After the intraspinal injection at three days post-injury, the rats received gentamicin for four days and Ringer's and Rimadyl for three days 7, 15 . Bladders were manually emptied twice daily until reflex voiding occurred. Rats were monitored daily throughout the experiments. Rats were fixed at 15 min, one, four, or six weeks after injection. All rats survived without requiring pain or distress treatment.
Motor function assessment
Overground walking ability was assessed using the BBB test 37, 38 weekly for six weeks postinjection (n = 10/group). Rats were tested for 4 min by two testers unaware of the treatments. Rats were familiarized with the open field and baseline values were determined before surgery. Scores were averaged per experimental group. Higher motor functions were assessed at six weeks post-injury using the BBB sub-score 39,40 as previously described (n = 10/group) 7 . Scores were averaged per experimental group. Sensorimotor function of the hind limbs was assessed before (baseline) and at six weeks post-injection using horizontal ladder walking (n = 10/group) 7, 41, 42 . Slips of the foot and part of lower leg and slips of the full leg were counted and expressed as a percentage of the total number of steps. Scores were averaged per experimental group.
Histological procedures
Rats were anaesthetized and transcardially perfused with 300 ml PBS followed by 400 ml 4 
Immunocytochemistry
Tissue sections were incubated in 5% normal goat serum (Vector Labs, Burlingame, CA, USA) and 0.03% Triton X-100 (Sigma-Aldrich) in PBS for 1 h followed by the primary antibody for 2 h at room temperature and then overnight at 4 °C. Rabbit polyclonal antibodies against glial-fibrillary acidic protein (GFAP) were used to detect astrocytes Numbers were averaged per experimental group.
Measurement of nervous tissue sparing
Cresyl violet-stained sections of rats that survived for four weeks post-injection were used to determine the volume of spared tissue in the damaged spinal cord segment using the Cavalieri estimator function of StereoInvestigator® (MicroBrightField, Inc.) 7, 43 . Analysis was performed by personnel blinded to the experimental groups (n = 6/group). The Gundersen .
In vitro assessment of the protective effect of ESHU
To assess ESHU's cell protective ability we kept BMSCs in vitro under oxidative stress, which is known to contribute to intraneural cell transplant loss 23, 24 . A total of 4x105 cells were incubated in 100 μl ESHU or PBS with 200 μM hydrogen peroxide (H2O2; SigmaAldrich) for 24 h at 37°C. Then, 100 μl Trypan Blue (Sigma-Aldrich) was added and viable (Trypan Blue-negative) cells were quantified in a hematocytometer and expressed as a percentage of all counted cells. Results from nine samples from three independent experiments were averaged. In nine samples from three independent experiments, the average number of BMSCs expressing caspase 3, a marker for apoptosis, and 8-Oxo-2'-deoxyguanosine (8-oxo-dG), a marker for DNA damage, were determined (see above).
Details on caspase 3 and 8-oxo-dG staining are described in 2.8. Immunocytochemistry.
Quantification of ESHU's antioxidant ability
ESHU's ability to scavenge H2O2 relative to PBS was measured using a H2O2 quantification kit (National Diagnostics, Atlanta, GA, USA) which colorimetrically measures Xylenol Orange-Ferric iron complex resulting from H2O2-mediated oxidation of ferrous iron. The linear standard curve of this assay is 15-100 ng/ml. We added 30 ng/ml H2O2 (Sigma-Aldrich) to ESHU or PBS which was kept in reagent buffer for 30 min following the manufacture's guidelines. Absorbance was measured (Victor 2V 1420; Perkin-Elmer, Waltham, MA, USA) and the values from three independent experiments were averaged.
Statistical analysis
Two-tailed Student's T-test was used to determine differences in cell numbers in vivo and in vitro and in H2O2 concentrations in vitro. One-way ANOVA with Tukey's post-hoc test was used to assess differences in macrophages and nervous tissue sparing. Repeated measures ANOVA with Tukey's post hoc test determined differences in functional performances. Differences between groups were considered significant when p < 0.05.
RESULTS
BMSC transplant survival
We investigated whether ESHU protects transplanted BMSCs from death in damaged nervous tissue using a spinal cord contusion model. At 15 min post-injection, rounded
BMSCs were present in the injury when mixed in either ESHU (Fig. 2a) or PBS (Fig. 2b) . One week post-injection, in both groups many spindle-shaped cells were also found (Figs. 2c,   2d ). At 4 and 6 weeks, hardly any cells could be found in or near the contusion site after injection of BMSCs in ESHU (Fig. 2e ) or in PBS (Fig. 2f) . The temporal morphological profile of the grafted cells is in accordance with earlier observations 15 . Also, GFAP staining (Figs. 2a-f) was similar as previously described 7, 15 . We found that 73 ± 17 % (SEM; n =6) of transplanted cells had survived in ESHU while 21 ± 8 % (SEM; n = 6) survived in PBS (Fig.   2g ), which represents a significant (p < 0.05) 3.5-fold increase in survival in ESHU compared with PBS. At four weeks post-injection, in both groups < 1 % of the cells has survived in the injury site. The data show that ESHU does not affect BMSC transplant morphology and protects against early death resulting in increased transplant presence at one week post-injection. 
Effect of BMSC transplant survival on neuroprotection
Because BMSC transplant survival is associated with neuroprotection 15 we assessed whether ESHU-promoted transplant survival rendered enhanced tissue sparing ( Fig. 3a-d) .
The results demonstrated that the volume of spared tissue in rats with the transplant in ESHU is 66 % larger (p < 0.05; n = 6/group) than in rats with the transplant in PBS at four weeks post-transplantation (Fig. 3e) . ESHU only had no effect on spared tissue volume in the damaged area (Fig. 3e) . The data suggest that increased survival of intraneural BMSC transplants early after injection enhances neuroprotection of nervous tissue.
Effect of BMSC transplant survival on motor recovery
After spinal cord contusion, motor performance depends in part on the amount of nervous tissue at the injury site 7 . We examined whether augmented neuroprotection by BMSC transplants with ESHU-enhanced survival affected motor function recovery. We found that rats with the transplant in ESHU performed significantly (p<0.05; n = 10/group) better in overground walking than rats with BMSC in PBS at 4-6 weeks post-injury (Fig. 4a) .
Rats with BMSC in ESHU performed better than rats with ESHU or PBS alone at 1-6 weeks post-injury and rats with BMSCs in PBS walked better overground than rats with ESHU or PBS alone only at 1-3 weeks post-injury (Fig. 4a) . At 6 weeks, rats with BMSCs in ESHU showed consistent (>95%) weight-supported plantar steps with frontlimb-hindlimb coordination. The control transplanted rats were less consistent (50-95%) making such steps, whereas rats with ESHU or PBS only were less consistent and lacked frontlimbhindlimb coordination. During the 4th-6th week after injection, overground walking was increased by 1.7 ± 0.4 points on the BBB scale in rats with the transplant in ESHU which was significantly (p < 0.05; n = 10/group) higher than the increase in the other groups (Fig.   4b ). Higher motor functions of the hindlimbs were significantly improved (p < 0.05; n = 10/group) by 74% in rats with BMSC in ESHU compared with BMSCs in PBS at 6 weeks post-injury (Fig. 4c) . Sensorimotor function was significantly increased (p < 0.05; n = 10/group) in rats with the transplant in ESHU compared with the other three groups at 6 weeks post-injury (Fig. 4d) . Rats receiving the transplant in PBS had significantly improved sensorimotor function compared with rats with ESHU or PBS alone (Fig. 4d) . 
Inflammatory response
Macrophages invade damaged nervous tissue and contribute to cell death 19 . ESHU breakdown products could carry negative charges and so affect macrophage presence 44 .
We tested the possible influence of macrophages on ESHU's protective capacity by assessing their presence in the injury after injection of BMSCs in ESHU (Fig. 5a-c) or PBS ( Fig. 5d-f) , or ESHU or PBS only. The results demonstrated similar macrophage presence between all groups at one (Fig. 5g) and four (Fig. 5h) weeks post-injection, suggesting that ESHU is non-immunogenic. The data indicate that macrophages are not implicated in ESHU-mediated transplant survival.
Oxidative stress-mediated cell death in vitro
We tested whether ESHU protects BMSCs from H2O2-mediated death in vitro (Fig. 6a ) and found that survival was increased four-fold in ESHU (62 ± 6%, SEM; n = 9) compared with PBS (15 ± 2%, p < 0.05, n = 9; Fig. 6b ). ESHU resulted in an almost two-fold decrease in
BMSCs positive for caspase 3 or 8-oxo-dG (p < 0.05, n = 9; Fig. 6c ). To explore ESHU's cell protective effect we assessed its proficiency in scavenging H2O2. We found that ESHU decreased the amount of H2O2 by 10 % (3 ng/ml) in 30 min compared with PBS (p < 0.05, n = 9; Fig. 6d ), suggesting ESHU-mediated oxidation of H2O2. The data show that ESHU scavenges H2O2 and protects against oxidative stress-mediated cell death. 
DISCUSSION
We show that ESHU, a synthetic injectable reverse thermal gel, protects transplanted
BMSCs from death thereby prolonging their presence in damaged nervous tissue and leading to enhanced tissue sparing accompanied by improved motor function recovery.
Our study demonstrates that improved intraneural BMSC transplant survival enhances their effects on repair, which may have widespread impact on BMSC-based therapies for tissue repair.
The inclusion of ESHU enhanced BMSC presence in a contusion in the adult rat spinal cord.
This effect was transient possibly due to degradation of ESHU 25 . When mixed in culture medium, BMSC presence was significantly lower in the contusion site [15] [16] [17] [18] 47 . Possibly ESHU retains BMSCs better in the contusion (i.e., the site of injection) compared with culture medium, resulting in the higher numbers. Previously we showed that about 2.4% of GFPexpressing BMSCs in culture medium leaked or migrated away from a contusion 15 .
Therefore, the present results suggest that ESHU protects transplants in the contused spinal cord tissue during the first week post-injection, which is a critical time period for BMSC-mediated neuroprotection 15 .
The ESHU-mediated increase in BMSC survival in the contused spinal cord resulted in anatomical (tissue sparing) and functional (motor/sensorimotor) improvements. Spared tissue volume was not affected by ESHU alone, indicating that the neuroprotection was elicited by the increased survival of the transplant. Previously, we showed that the neuroprotective effects of BMSC transplants are greatest during the first week postinjury 15 . The current finding demonstrates that the efficacy of an intraspinal BMSC transplant to elicit neuroprotection depends on its degree of survival and that increased survival leads to increased spared tissue volumes. Neuroprotection by intraneural BMSC transplants is thought to result from paracrine effects [11] [12] [13] [14] . Our finding that increased transplant survival results in increased tissue sparing may imply that the magnitude of neuroprotection elicited by the transplants depends on the concentration and/or availability of secreted growth factors mediating paracrine actions.
Overground walking and higher motor and sensorimotor functions of the paralyzed hindlimbs were further improved in rats that received BMSCs in ESHU. The improvements in overground walking were particularly evident during the second half of the 6-week period. It was demonstrated that BMSC transplant-mediated improvements in motor function recovery after spinal cord [4] [5] [6] [7] 18 and brain [50] [51] [52] injury are correlated with the amount of spared nervous tissue 7, 53 . Thus, in our study, neuroprotection elicited by BMSC transplants with ESHU-increased survival likely contributes to the observed improved motor function recovery. At present the anatomical correlates underlying improved motor recovery are not completely known but may involve increased numbers of descending axons conducting the actual motor activity 7 and/or increased myelination providing better signal conduction 53, 54 , which both could result from neuroprotection.
In search of potential mechanisms underlying ESHU-mediated BMSC protection, we assessed macrophage presence in the contusion. Macrophages are naturally present in damaged nervous tissue and contribute to the death of neural and transplanted cells 16, 17, 19 . Oxidation of ESHU could lead to carboxylates whose negative charges might inhibit adhesion of macrophages 44 thereby limiting their contribution to cell death. We found that the number of macrophages in the contusion was similar with or without the presence of ESHU. BMSCs are hypoimmunogenic, lacking MHC class II and co-stimulatory molecules for effector T cell induction 48 , and suppress T cell proliferation 49 ; thus the adaptive immune response is unlikely to be largely involved in allogeneic BMSC death. Our data suggest that the protective effects of ESHU result from direct effects on the transplant rather than indirect effects involving macrophages.
Another possible mechanism underlying ESHU-promoted BMSC survival is antioxidation.
Reactive oxygen species (ROS) accumulate rapidly in damaged nervous tissue and induce oxidative stress leading to cell death [20] [21] [22] [23] [24] . We used H2O2 to determine whether ESHU has the ability to scavenge ROS and thus mediate antioxidant effects. H2O2 is amply present in damaged nervous tissue 45 . We found that a 16 % ESHU solution removed 3 ng H2O2 in a 30 min time period. Assuming continuous activity at 3 ng/30 min, ESHU removed ~ 20% of added H2O2 in our in vitro assay of ESHU's ability to protect BMSCs, which elicited a 47 % increase in their survival relative to PBS. The ability to scavenge ROS may be exerted through its urethane groups 28, 29 . Possibly ESHU's antioxidant effects may be increased with higher concentrations 46 . Our observations point at antioxidation as a potential mechanism of ESHU-promoted BMSC transplant survival. ROS are known to contribute to transplanted cell death 23, 24 . Future studies need to define molecular factors in ESHU's protective actions and whether the protection by ESHU in vivo is concentrationdependent.
CONCLUSIONS
We demonstrate that the reparative effects of a BMSC transplant are enhanced by promoting their survival. This finding critically impacts current and future BMSC-based therapies for the central nervous system. ESHU's ability to gel at body temperature allows for injection (i.e., minimally invasive) into closed injuries. Besides reducing oxidative stress and serving as a matrix for cells, ESHU can also be used to deliver drugs and/or functionalized with bioactive molecules to affect targeted biological events. These benefits render ESHU an important candidate in future therapies for the traumatized or degenerated nervous system. Furthermore, because oxidative stress is part of many diseases where BMSCs can be effective, such as cardiac myopathy and peripheral arterial disease, ESHU may have wide therapeutic relevance.
